Skip to main content
Journal of Patient-Reported Outcomes
Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial

Fig. 1

PKDD item response distributions at baseline. aItems 1, 2, and 4–7 have response options coded to an 11-point numerical rating scale. Item 3 is rated on a 5-step verbal descriptor scale so only responses from 0 to 4 are available. See Table 1 for a full summary of PKDD items. In brief, item 1, tiredness at its worst; 2, tiredness after daily activities; 3, jaundice; 4, bone pain; 5, shortness of breath; 6, energy at the beginning of the day; 7, energy at the end of the day. PKDD Pyruvate Kinase Deficiency Diary

Back to article page